Genmab — April 2017

[Helge_LarsenPI-redaktør]

God morgen.

[Sukkeralf]

Norsk cancerselskab rejser 345 mio i børsnotering

Et norsk biotekselskab, der udvikler lægemidler mod kræft i blodet, er blevet børsnoteret i Oslo og har ved den lejlighed rejst, hvad der svarer til 345 mio. kr.

(medwatch.dk)

[Nickstar]

Bud, Luk 1283

[bibob]

1280

[Legolas23]

1292

[Nickstar]

[resten]

1300 rent.

[resten]

Ingen vil være ude over påsken

[Nickstar]

dejligt med optimisme.....eller måske rettere..realisme

[Alelau]

Det hele afhænger af AB - smutter de på købssiden kan vi hurtigt komme på 1300. Deres kurs i dag er noget slingrende, men det vil da være skønt at se dem på købssiden

[gentogen]

Fra AACR: 4617 / 2 - Daratumumab combined with CD38(-) natural killer cells armed with a CS1 chimeric antigen receptor for the treatment of relapsed multiple myeloma

[gentogen]

Our data further show that Dara activates but does not induce apoptosis in CD38(-) NK cells. Thus, we hypothesize that the combination of Dara and CD38(-) CS1-CAR NK cells can show a synergistic effect on tumor eradication and prevention of MM relapse. Our data indeed demonstrated that the combination of CS1 CAR NK cells with CD38(-) NK cells but not with CD38+ NK cells shows a synergistic effect to eradicate MM cells

[gentogen]

Program Planner

(www.abstractsonline.com)

[gentogen]

Both CS1 and CD38 are tumor-associated antigens expressed on the surface of MM cancer stem-like cells, suggesting that dual targeting of CS1 and CD38 may prevent relapse. Thus, we investigated the combination therapy with Dara and CS1-CAR NK cells for the treatment of relapsed MM.

[gentogen]

Overall, we have found Dara was effective in 4 of 6 evaluable non-ETP T-ALL samples. In summary, we found dara is a highly effective novel monotherapy for T-ALL in preclinical models. Based on these results, we are developing an early phase trial for children and young adults with relapsed/refractory T-ALL.

[gentogen]

Titel på denne: 2642 / 1 - Preclinical efficacy of daratumumab in acute lymphoblastic leukemia

[gentogen]

We demonstrate striking efficacy of dara monotherapy in 6 of 7 ETP-ALL samples with reduction of pb and splenic blasts

[gentogen]

Program Planner

(www.abstractsonline.com)

[gentogen]

2644 / 3 - SY-1425, a selective RARα agonist, induces high levels of CD38 expression in RARA-high AML tumors creating a susceptibility to anti-CD38 therapeutic antibody treatment

[gentogen]

By inducing the expression of CD38, SY-1425 in combination with DARA elicits tumor cell death and NK cell activation. Based on these findings, a phase 2 clinical study with SY-1425 in combination with an anti-CD38 antibody is planned in AML using an RARA biomarker patient selection strategy.